Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

VOS

Other · developed by Aurinia Pharmaceuticals

Phase 2/3 Most advanced trial (none active)
AUPH Developer
1 Registered trials

What is VOS?

VOS is an investigational drug studied in Dry Eye Syndrome, Keratoconjunctivitis Sicca.

At a glance

Drug type
Other
Therapy area
Ophthalmology
Developer
Aurinia Pharmaceuticals Inc. (AUPH)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04147650 Phase 2/3 Dry Eye Syndrome Completed AUPH

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dry Eye SyndromeKeratoconjunctivitis Sicca

More from Aurinia Pharmaceuticals

Voclosporin FDA approved Aritinercept Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AUPH page.

Follow AUPH, the company behind VOS

See AUPH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AUPH catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.